Business Description
Aroa Biosurgery Ltd
NAICS : 423450
SIC : 5047
ISIN : NZARXE0001S1
Share Class Description:
ASX:ARX: Ordinary SharesTotal Employee Number:
249Description
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.24 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 0.54 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 7.93 | |||||
Beneish M-Score | -2.61 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.5 | |||||
3-Year EBITDA Growth Rate | 44.2 | |||||
3-Year Book Growth Rate | -4.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 42.22 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.99 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.18 | |||||
9-Day RSI | 41.04 | |||||
14-Day RSI | 43.57 | |||||
3-1 Month Momentum % | 16.38 | |||||
6-1 Month Momentum % | -7.53 | |||||
12-1 Month Momentum % | 18.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.77 | |||||
Quick Ratio | 4.4 | |||||
Cash Ratio | 1.67 | |||||
Days Inventory | 190.58 | |||||
Days Sales Outstanding | 63.57 | |||||
Days Payable | 98.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | 0.14 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 85.53 | |||||
Operating Margin % | -0.6 | |||||
Net Margin % | 4.5 | |||||
EBITDA Margin % | 11.46 | |||||
FCF Margin % | 6.56 | |||||
OCF Margin % | 10.15 | |||||
ROE % | 4.71 | |||||
ROA % | 3.97 | |||||
ROIC % | -0.63 | |||||
3-Year ROIIC % | 75.91 | |||||
ROC (Joel Greenblatt) % | 11.24 | |||||
ROCE % | 6.33 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 54.09 | |||||
Forward PE Ratio | 49.17 | |||||
PE Ratio without NRI | 54.09 | |||||
Price-to-Owner-Earnings | 54.09 | |||||
PS Ratio | 2.49 | |||||
PB Ratio | 2.48 | |||||
Price-to-Tangible-Book | 3.13 | |||||
Price-to-Free-Cash-Flow | 39.67 | |||||
Price-to-Operating-Cash-Flow | 24.79 | |||||
EV-to-EBIT | 33.79 | |||||
EV-to-Forward-EBIT | 16.21 | |||||
EV-to-EBITDA | 18.88 | |||||
EV-to-Forward-EBITDA | 11.69 | |||||
EV-to-Revenue | 2.16 | |||||
EV-to-Forward-Revenue | 1.92 | |||||
EV-to-FCF | 32.96 | |||||
Price-to-GF-Value | 0.78 | |||||
Price-to-Graham-Number | 2.7 | |||||
| Price-to-Net-Current-Asset-Value | 4.25 | |||||
| Price-to-Net-Cash | 59.5 | |||||
Earnings Yield (Greenblatt) % | 2.96 | |||||
FCF Yield % | 2.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aroa Biosurgery Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 86.603 | ||
| EPS (TTM) (A$) | 0.011 | ||
| Beta | 1.1751 | ||
| 3-Year Sharpe Ratio | -0.13 | ||
| 3-Year Sortino Ratio | -0.16 | ||
| Volatility % | 41.5 | ||
| 14-Day RSI | 43.57 | ||
| 14-Day ATR (A$) | 0.024009 | ||
| 20-Day SMA (A$) | 0.6205 | ||
| 12-1 Month Momentum % | 18.42 | ||
| 52-Week Range (A$) | 0.495 - 0.8 | ||
| Shares Outstanding (Mil) | 346.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aroa Biosurgery Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aroa Biosurgery Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2025 | 2025-05-21 09:00 | 0.44 (+1.15%) | ||
| Fourth quarter earnings results for 2025 | 2025-05-21 | 0.44 (+1.15%) | ||
| Third quarter earnings conference call for 2025 | 2025-01-30 09:00 | 0.61 (-16.55%) | ||
| Third quarter earnings results for 2025 | 2025-01-30 | 0.61 (-16.55%) | ||
| Second quarter earnings conference call for 2025 | 2024-11-22 10:00 | 0.65 (+0.78%) | ||
| Second quarter earnings results for 2025 | 2024-11-22 | 0.65 (+0.78%) | ||
| General meeting for 2024 | 2024-08-02 12:00 | 0.63 (-1.56%) | ||
| First quarter earnings conference call for 2025 | 2024-07-31 09:00 | 0.63 (+1.61%) | ||
| First quarter earnings results for 2025 | 2024-07-31 | 0.63 (+1.61%) |
Show
Entries
Aroa Biosurgery Ltd Frequently Asked Questions
What is Aroa Biosurgery Ltd(ASX:ARX)'s stock price today?
The current price of ASX:ARX is A$0.60. The 52 week high of ASX:ARX is A$0.80 and 52 week low is A$0.50.
When is next earnings date of Aroa Biosurgery Ltd(ASX:ARX)?
The next earnings date of Aroa Biosurgery Ltd(ASX:ARX) is .
Does Aroa Biosurgery Ltd(ASX:ARX) pay dividends? If so, how much?
Aroa Biosurgery Ltd(ASX:ARX) does not pay dividend.
Press Release
Articles on Aroa Biosurgery Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers